Implications of Selection Bias Due to Delayed Study Entry in Clinical Genomic Studies.

ABSTRACT:

Importance

Real-world data sets that combine clinical and genomic data may be subject to left truncation (when potential study participants are not included because they have already passed the milestone of interest at the time of study recruitment). The lapse between diagnosis and molecular testing can present analytic challenges and threaten the validity and interpretation of survival analyses.

Observations

Effects of ignoring left truncation when estimating overall survival are illustrated using data from the American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange Biopharma Collaborative (GENIE BPC), and a straightforward risk-set adjustment approach is described. Ignoring left truncation results in overestimation of overal

SUBMITTER: Brown S 

PROVIDER: S-EPMC9190030 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature